DrugPatentWatch Database Preview
Drugs in Development Information for Geldanamycin
» See Plans and Pricing
What is the development status for investigational drug Geldanamycin?
Geldanamycin is an investigational drug.
There have been 15 clinical trials for Geldanamycin.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2004.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, and Kidney Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center, and Esanex Inc.
Summary for Geldanamycin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 4,377 |
| WIPO Patent Applications | 2,969 |
| Japanese Patent Applications | 13 |
| Clinical Trial Progress | Phase 2 (2004-07-01) |
| Vendors | 40 |
Recent Clinical Trials for Geldanamycin
| Title | Sponsor | Phase |
|---|---|---|
| Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma | Esanex Inc. | Phase 1 |
| Dose Escalation of IPI-493 in Hematologic Malignancies | Infinity Pharmaceuticals, Inc. | Phase 1 |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Geldanamycin
Top disease conditions for Geldanamycin
Top clinical trial sponsors for Geldanamycin
US Patents for Geldanamycin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
